A Phase 3 trial of Ranolazine (CV T...

A Phase 3 trial of Ranolazine (CV Therapeutics, Inc., Palo Alto, CA) in stable angina met its primary efficacy endpoint. make liables on a background antianginal therapy and ranolazine experienced greater increases in symptom-limited exercise duration at hollow drug concentrations than those forward placebo. The multinational trial involved 823 enslaves in a randomized, double-blind, placebo-controlled research design. It used a parallel dispose to assess the safety and efficacy of the close attention drug after 12 weeks of treatment. controls received twice daily doses of ranolazine 750 mg 1000 mg or